Atypical antipsychotics induce pre-diabetic symptoms in some but not all patients, characterized most notably by elevated weight. The side effect profiles of the various drugs in the class differ, however, raising the possibility of drug-specific mechanisms for similar side effects. We used physiogenomic analysis, an approach previously employed to study the genetics of drug and diet response, to discover and compare genetic associations with weight profiles observed in patients treated with olanzapine and risperidone as an approach to unraveling contrasting mechanistic features of both drugs. A total of 29 single nucleotide polymorphisms (SNPs) were selected from 13 candidate genes relevant to two potential pharmacological axes of psychotropic-related weight profiles, appetite peptides and peripheral lipid homeostasis. We applied physiogenomic analysis to a cross-section of 67 and 101 patients being treated with olanzapine and risperidone, respectively, and assessed genetic associations with the weight profiles. Weight profiles in patients treated with olanzapine were significantly associated with SNPs in the genes for apolipoprotein E, apolipoprotein A4 and scavenger receptor class B, member 1. Weight profiles in patients treated with risperidone were significantly associated with SNPs in the genes for leptin receptor, neuropeptide Y receptor Y5 and paraoxonase 1. These results are consistent with contrasting mechanisms for the weight profile of patients treated with these drugs. Genes associated with olanzapine weight profiles may be related to peripheral lipid homeostatic axes, whereas those associated with risperidone's may be related to brain appetite peptide regulation. Future physiogenomic studies will include neurotransmitter receptor SNPs and validation in independent samples.
Introduction
Atypical antipsychotics (AAPs) are associated with weight gain, although excess weight does not develop in all patients. [1] [2] [3] Hypertriglyceridemia ( > 600 mg/dl) may develop in as little as 3 months after initial exposure to these drugs. 4 The AAPs are much more frequently associated with diabetes than are the 'typical' antipsychotics. In a study of more than 38 000 patients, those on AAPs were 9% more likely to have diabetes than those treated with 'typical' antipsychotics. 5 In September 2003, the Food and Drug Administration required re-labeling of all AAPs to inform physicians about these risks.
Olanzapine and clozapine carry the highest risk for these side effects. 6 Several population-based nested case-control studies have shown that olanzapine is an independent risk factor for diabetes mellitus in patients with schizophrenia. 7, 8 Olanzapine is a thienobenzodiazepine with high affinities for the D 1 , D 2 , D 4 , 5HT 2A , 5HT 2C , 5HT 3 , H 1 , alpha 1 and M 1 receptors. It is a substrate for the cytochrome P450 1A2 (CYP 1A2) and for the UDP-glucuronosyltransferase 1A4 (UGT 1A4) 9 and has no active metabolites. 10, 11 Risperidone, another drug in this class, has a different side effect profile. Weight gain is less pronounced than with olanzapine, 12 but it is much more likely to increase prolactin. Risperidone is a benzisoxazole with high affinities for the D 2 , 5HT 2A , 5HT 2C , a 1 and a 2 receptors. It is a substrate for the cytochrome P450 2D6 and 3A (CYP 2D6 and CYP 3A) 13 and has an active metabolite, 9-hydroxyrisperidone, with a comparable receptor affinity profile. 10, 11 Study of the AAP pharmacological feature, which is responsible for the development of pre-diabetic complications in vulnerable populations, has principally centered around weight gain caused by these medications. Histamine 1 (H 1 ) and serotonin 2C (5HT 2C ) receptor antagonism were among the most important pharmacologic mechanisms discussed. 14 Antagonism of H 1 and 5HT 2C receptors is believed to stimulate appetite and prevent satiety, respectively. 15 Other mechanisms that may lead to weight gain are drug-induced elevations in serum leptin, neuropeptide Y (NPY) or ghrelin. 16, 17 Patients taking AAPs are also known to be at risk for elevations in serum triglycerides and glucose. 4, 18 The mechanism behind hypertriglyceridemia is not known. In one case report, olanzapine-induced hyperlipidemia resolved when olanzapine levels disappeared, whereas weight persisted. 19 Genetically tractable metabolic differences could account for the variability in druginduced weight gain. 1, 2, 18, [20] [21] [22] [23] The availability of comprehensive genomic databases and massively parallel SNP genotyping technology cannot be adequately handled by traditional statistical methods; it requires the development of new statistical methods. This report is the first use in psychiatry of one of these new methods, which we have called physiogenomics. [24] [25] [26] Physiogenomics is a medical application of sensitivity analysis and systems engineering, which we had previously applied to the study of drug and diet responses. 24, 25 Sensitivity analysis is the study of the relationship between input and output as determined by each system component. 27 Physiogenomics utilizes genes as the components of the system. Gene variability, measured by single nucleotide polymorphisms (SNPs), is correlated with physiological characteristics in a population, the output. With the advent of nanotechnology-based gene arrays, parallel processing of gene variability is practically possible at the level of physiological systems. Although single-gene mutations are the basis of most inborn errors of metabolism, partial penetrance of genes interlinked in networks is more relevant to phenotypes common in clinical neuroscience. In physiogenomics, markers of gene variation are analyzed to discover statistical associations with physiological characteristics. 26 The phenotypes are measured in populations of individuals either at baseline or after they have been similarly exposed to environmental challenges or interventions, including drugs and diet. The physiogenomic approach affords testing broad hypotheses about mechanistic features of drug effects. By relating the physiological response to natural gene variation, we gain valuable mechanistic insight. We also gain a practical way of predicting the response when the gene variation is known. In this report, we have extended physiogenomics to a comparison of two AAP medications, olanzapine and risperidone.
Materials and methods

Subjects and study design
Patients were recruited as part of ongoing pharmacogenetic studies at the Institute of Living (Hartford, CT, USA) and at three Kentucky state hospitals (Lexington, KY, USA). These hospitals treat patients with severe and persisting mental illness. From this study, 67 patients taking olanzapine and 101 patients taking risperidone who were willing to provide a blood sample were selected for genotyping. The demographic characteristics of the patient population are presented in Table 1 . To be eligible, patients had to have a current prescription of olanzapine or risperidone. All patients had an examination during which their weight was determined.
Candidate gene selection
We selected eight genes related to peripheral lipid homeostasis and five related to central appetite regulation, as summarized in Table 2 . From the lipid homeostasis axis, we selected representative low-density lipoprotein (LDL) and high-density 29 On the axis of appetite regulation, we focused on hypothalamic hormones and their receptors. The hormone genes we genotyped were NPY, ghrelin precursor (GHRL) and galanin (GAL). NPY is a key appetite regulator which interacts with GHRL, leptin, GAL and other hormones to orchestrate feeding behavior and appetite. 30 Leptin receptor (LEPR) and NPY receptor Y5 (NPY5R) are peptide hormone receptors involved in appetite regulation.
Laboratory analysis
A blood sample was obtained for each patient and DNA extracted. 31 Genotyping was performed using the Illumina BeadArray platform and the GoldenGate assay. 32, 33 Table 3 lists the assay information and observed allele frequencies for the SNPs used in this study.
Data analysis
Statistical analysis utilized the R Statistics Language and Environment. [34] [35] [36] [37] Covariates were analyzed using multiple linear regression, and selected using the stepwise procedure. To test for association with SNPs, the residual of weight from the covariate model was tested using linear regression on the SNP genotypes. SNP genotype was coded numerically according to carrier status for the minor allele: 0 for Abbreviation: SNP, small nucleotide polymorphisms.
Physiogenomics weight olanzapine risperidone G Ruaño et al non-carriers, 1 for single carriers and 2 for double carriers. The F-statistic P-value for the SNP variable from the analysis of variance (ANOVA) was used to evaluate the significance of association. To test the validity of the ANOVA P-values, we performed an independent calculation of the P-values using permutation testing. The ranking of the first three SNPs was identical under permutation and ANOVA analyses (data not shown). To account for the multiple testing of 29 SNPs, we calculated adjusted P-values using Benjamini and Hochberg's false discovery rate (FDR) procedure. [38] [39] [40] In addition, we evaluated the power for detecting an association based on the Bonferroni multiple comparison adjustment. We calculated for each SNP the effect size relative to the s.d. necessary for detection of an association at a power of 80% (20% false-negative-rate) using the formula
where a is the desired false-positive rate (a = 0.05), b the false negative rate (b = 1ÀPower = 0.2), c the number of SNPs, z a standard normal deviate, N the number of subjects, f the carrier proportion and D the difference in average weight between carriers and non-carriers expressed relative to the s.d. 41 
LOESS representation
We used a locally smoothed function of the SNP frequency as it varies with weight to visually represent the nature of an association. LOESS (LOcally wEighted Scatterplot Smooth) is a method to smooth data using a locally weighted linear regression. 42, 43 At each point in the LOESS curve, a quadratic polynomial is fitted to the data in the vicinity of that point. The data are weighted such that they contribute less if they are further away, according to the tricubic function
where x is the abscissa of the point to be estimated, the x i are the data points in the vicinity, and d(x) is the maximum distance of x to the x i . 
Abbreviations: APOA, apolipoprotein A; APOB, apolipoprotein B; APOE, apolipoprotein E; Chr, chromosome location of the gene; Freq, frequency (0.00-1.00) of the minor allele in the study population; GAL, galanin; GHRL, ghrelin precursor; LEPR, leptin receptor; Maj, sequence of the most common allele, major; Min, sequence of the least common allele, minor; NPY, neuropeptide Y; NPY5R, neuropeptide Y receptor Y5; PON1, paraoxonase 1; SCARB, scavenger receptor class B.
Results Figure 1 depicts the weight profiles in the olanzapine and risperidone study populations. These distributions are approximately normal. The mean weight was 83 kg for olanzapine vs 78 kg for risperidone. This difference was not statistically significant. We tested the potential covariates of age, gender, race and site (Kentucky or Connecticut) for association with weight using multiple linear regression. Only gender was found to be significantly associated (P = 0.033) in the risperidone-treated group where 4.5% of the variance is explained by gender, with men being 8 kg heavier on average. No other significant covariate was found in either treatment group. Table 4 lists the results of the association tests, comparing olanzapine and risperidone treated groups. We found that SNPs in APOE, APOA4 and SCARB1 were significantly associated with the weight profile in the olanzapine-treated group but not in the risperidone counterpart. Conversely, we found that SNPs in LEPR, PON1 and NPY5R were significantly associated with the weight profile in the risperidone group but not in the olanzapine counterpart. The FDR-corrected Pvalues yield an estimate of the false-positive rate. For the risperidone-specific associations (LEPR, PON1, NPY5R) and for the olanzapine-specific associations (APOE, APOA4, SCARB1) these values are, respectively, < 1 and < 7%. We attribute these differences to the larger sample size of the risperidone-treated group. All remaining genes showed no significant association in either treatment group, and no gene showed significant associations in both. We also list in Table 4 the effect size D relative to s.d. needed to reach significance under the Bonferroni adjustment. Figures 2 and 3 show detailed representations of the physiogenomic analysis for olanzapine and risperidone, respectively. Each plot contains three components: the distribution of the phenotype (thin line), the genotype of each individual patient (circles) and the LOESS fit of the allele frequency as a function of phenotype (thick line). In each of three graphs, the abscissa represents each patient's weight (kg), which is the phenotype. The ordinate indicates the allele frequency for the LOESS curve. For clarity's sake, axis labels for the genotypes and distribution curve are not shown. The genotypes are drawn on three levels: non-carriers of the minor allele at the bottom, singlecarriers in the middle and double-carriers at the top. The scale for the distribution curve is arbitrary.
The first panel in Figure 2 shows the LOESS curve for SNP rs7412 of the APOE gene. The frequency of the minor allele is below 20% in subjects with a weight of 40-60 kg, whereas it approaches 40% in subjects above 100 kg in weight. This finding indicates a strong association between the APOE marker and weight. As the frequency of the minor allele is higher in the high spectrum of the weight distribution, APOE SNP rs7412 is considered a risk marker for olanzapine. In contrast, the first panel in Figure 3 shows the LOESS curve for SNP rs8179183 of the LEPR gene. The frequency of the minor allele is 20% in subjects with weight of 40-60 kg, whereas it approaches 0% above 100 kg. This finding points to another strong association, in this case between LEPR and weight. However, as the frequency of the minor allele is higher in the low spectrum of the weight distribution, LEPR SNP rs8179183 is considered a protective marker for risperidone.
Discussion
This study shows that genetic associations with weight profiles established for genes in pathways encompassing appetite peptides and peripheral lipid homeostasis differentiate olanzapine and risperidone. Risperidone weight profiles had central appetite relationships through leptin and NPY Y not found with olanzapine. Conversely, olanzapine weight profiles had apolipoprotein associations through ApoE and ApoA4 that risperidone did not. Thus, physiogenomic analysis affords the derivation of a 'genetic contour' for a drug, a series of mechanistic genetic links which can differentiate even drugs in the same class.
The strongest association (P < 0.001) was found in the risperidone-treated group with SNP rs8179183 in the leptin receptor, which causes an amino-acid change from lysine to asparagine (Lys 656 Asn). Leptin has an obvious role in regulating body weight. 44 This SNP in the leptin receptor was previously found to be associated with body weight in a sample of 1 873 subjects from 405 Caucasian nuclear families. 45 The leptin receptor also encompasses other SNPs that have been associated with weight and related phenotypes, in particular Gln 223 Arg. 46 There is significant linkage between these SNPs, and any or none of them could be the actual functional variation.
Another equally strong association (P < 0.001) in the risperidone group was with SNP rs705381 upstream of the gene PON1. PON1 is an arylesterase enzyme expressed in the liver and found in the bloodstream associated with APOA1 and HDL-c. The enzyme protects against organophosphate poisoning and prevents the accumulation of oxidized lipids in LDL in vitro. Oxidized lipids are involved in atherosclerosis, and genetic variation in PON1 has been associated Figure 2 Physiogenomic representation of the most significant genetic associations found in the olanzapine-treated group. Each plot contains three components: the distribution of the phenotype (thin line), the genotype of each individual patient (circles) and the LOESS fit of the allele frequency as a function of phenotype (thick line). In each of three graphs, the abscissa represents each patient's weight (kg) which is the phenotype. The ordinate indicates the allele frequency for the LOESS curve. For clarity's sake, axis labels for the genotypes and the distribution curve are not shown. The genotypes are drawn on three levels: non-carriers of the minor allele at the bottom, single-carriers in the middle and double-carriers at the top. The scale for the distribution curve is arbitrary. Figure 3 Physiogenomic representation of the most significant genetic associations found in the risperidone-treated group. Each plot contains three components: the distribution of the phenotype (thin line), the genotype of each individual patient (circles) and the LOESS fit of the allele frequency as a function of phenotype (thick line). In each of three graphs, the abscissa represents each patient's weight (kg), which is the phenotype. The ordinate indicates the allele frequency for the LOESS curve. For clarity's sake, axis labels for the genotypes and the distribution curve are not shown. The genotypes are drawn on three levels: non-carriers of the minor allele at the bottom, single-carriers in the middle and double-carriers at the top. The scale for the distribution curve is arbitrary.
with cardiovascular disease. 47 SNP rs705381 is mapped upstream of the gene in the promoter area (À161 C/T). This SNP has previously been associated with Alzheimer's disease. 48 A third association in the risperidone group was with SNP rs6837793 in the NPY5 receptor. NPY plays an important role in the integration of appetite and energy expenditure through the NPY Y1 and Y5 receptor subtypes. Moreover, the NPY Y1 receptor is highly expressed on human adipocytes, where it inhibits lipolysis. SNP rs6837793 is located in the promoter region between the Y1 and Y5 receptor genes, which are believed to be co-regulated by a single promoter. An other SNP in the same promoter region has been linked to serum triglyceride and HDL-c levels. 49 In the olanzapine group, the strongest association (P < 0.006) was found with SNP rs7412 in apolipoprotein E, which causes an amino-acid change (Arg 176 Cys) and is known as the e2 allele. The e2 allele is known to be associated with decreased LDL-c and increased triglyceride levels, 50 and is protective for Alzheimer's disease. 51 The e4 allele has also been linked to weight loss in Alzheimer's disease patients. 52 To investigate whether the observed associations might be due to linkage disequilibrium with neighboring genes, we performed a chromosome locus analysis using the HapMap data. 53 Using the r 2 -criterion for linkage, we observed linkage blocks, genomic regions within which most SNPs are physically linked. The following genes were linked with other genes in the same linkage block: APOE with TOMM40 (mitochondrial outer membrane protein TOM40) and APOC1 (apolipoprotein C-I precursor); APOA4 with ZNF259 (zinc-finger protein 259), APOA5 (apolipoprotein A-V), APOC3 (apolipoprotein C-III precursor) and APOA1 (apolipoprotein A-I preprotein); and PON1 with PON3. SCARB1 and the NPY1R/NPY5R promoter do not show significant linkage with other genes. Our HapMap analysis utilized the Utah reference population with Western European ancestry, which is the best match for the predominantly Caucasian patient populations in this study.
As the patients were not randomized to the treatment, it is possible that the results have been influenced by prior multiyear treatment with antipsychotics and other medications, other potential confounders and, particularly, treatment decisions. As it is well known that olanzapine can exacerbate obesity, 54 prescription of this drug may be biased towards lower weight patients. The lack of a significant difference in weight between olanzapine-and risperidone-treated patients is most likely owing to this confounding effect, which tends to oppose the actual drug effect. Our focus on contrasting factors between two drug treatment groups may minimize baseline effects that are shared between treatment groups. Confounding factors would be a much more serious problem if we were trying to differentiate the drugs clinically rather than genetically. We are helped by the unique properties of SNP markers. First, SNPs are inherited and stable DNA markers, which eliminates the ambiguity about cause and effect so common in epidemiological studies. Second, treatment decisions are independent of SNP markers (unknown by treating physicians), diminishing the possibility of treatment bias affecting the physiogenomic analysis.
This study is focused on a limited set of genes related to lipid metabolism and appetite peptides. The more recent genetic studies of antipsychotics and weight gain have focused on neurotransmitter receptors including serotonin receptor 5HT2 C , 55 ,56 a adrenergic receptors, 57 combinations of serotonin, dopamine and a adrenergic receptors 58 but a few of them have also explored peptides such as the brainderived neurotrophic factor 58 and leptin. 55 A genomewide scan study in patients taking antipsychotics pointed toward another appetite peptide, the peptide pro-melanin-concentrating hormone. 59 At this stage of our physiogenomic study, we have not included any of the neurotransmitter receptor gene variations because they will be the subject of subsequent research looking at entire families of serotonin, dopamine, adrenergic and histamine receptors. Some prior studies 56, 57 have associated neurotransmitter receptor gene variation with olanzapine weight gain. These gene variations may influence appetite during olanzapine treatment. Unfortunately, our study only tested peptide-related genes, some for the peptides themselves and others for their receptors. The possibility that neurotransmitter receptor gene variations may influence weight in our olanzapine patients cannot be excluded, but will have to wait for our future studies.
The associations reported here are suggestive, and three of them (PON1, NPY5R and LEPR) are statistically significant after correction for multiple comparisons. As most subjects were Caucasians (only 27% out of 168 individuals or 16% of the study were nonCaucasians), we lack power to detect racial associations or racial confounding effects. It is important that these results are validated in different populations before they can be accepted as fact. We are pursuing such studies and continue recruiting additional subjects.
Ascertaining genetic risk differences for patients on AAPs would have significant clinical utility. The specter of obesity may reduce compliance with antipsychotic regimens and lead to low self-esteem and social withdrawal in already marginalized patients. In a recent study, it was shown that 75% of patients on AAPs discontinue therapy within 18 months of treatment initiation. 60 The observed variability among individuals highlights the need for personalized recommendations of drug choice to minimize potential side effects, particularly for AAPs that are widely prescribed for many psychiatric disorders 61 and in children. 62 Obesity and pre-diabetic syndromes introduce serious vascular complications, underscoring the urgency of avoiding the progression to diabetes in the first place.
Personalized medicine and DNA-guided drug regimens allow physicians to tailor therapies based on individual patient characteristics, rather than the average properties of drugs in clinical trials. [63] [64] [65] [66] A drug with a higher average risk, for example, may be safe for those patients who inherited an ensemble of DNA markers with the most protective factors and the least risk factors. The ability to match a drug's genetic 'contour' with the DNA profile of an individual patient marks the beginning of high-resolution personalized pharmacotherapy for prevention of adverse drug reactions.
A recent review has stressed that off-patent typical antipsychotics have been largely abandoned in developed countries owing to their tardive dyskinesia risk. However, typical antipsychotics are frequently used in developing countries and pharmacogenetics may help to reduce their risk of developing tardive dyskinesia. 67 In 2006, risperidone became generic in some European countries and will soon become generic in the US. Olanzapine will become off-patent only a few years later. It is likely that the marketing of generic risperidone and olanzapine will be associated with substantial reductions in price, which may make pharmacogenetic testing for associated weight gain cost-effective.
